Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

fool.com - Motley Fool Transcribing - Ligand Pharma (LGND) Earnings Call Transcript
Ligand Pharma (LGND) Earnings Call Transcript
The Motley Fool

Thursday, February 26, 2026 at 8:30 a.m. ET Chief Executive Officer — Todd Davis Chief Financial Officer — Octavio Espinoza Vice President, Portfolio Strategy and Investments — Lauren Hay Senior Director, Investor Relations…

fool.com - Motley Fool Transcribing - Rhythm Pharma (RYTM) Earnings Call Transcript
Rhythm Pharma (RYTM) Earnings Call Transcript
The Motley Fool

Thursday, Feb. 26, 2026 at 8 a.m. ET Chairman, Chief Executive Officer, and President — David P. Meeker Executive Vice President, Head of North America — Jennifer Lee Chief Financial Officer — Hunter C. Smith Executive Vice…

thehindubusinessline.com - Eugia Pharma gets USFDA nod for Everolimus tablets
Eugia Pharma gets USFDA nod for Everolimus tablets
BusinessLine

Eugia Pharma Specialities, an arm of Aurobindo Pharma, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus tablets. The approved drug is a bioequivalent and therapeutically equivalent to…

marketbeat.com - Ascendis Pharma A/S $ASND Stake Decreased by Westfield Capital Management Co. LP
Ascendis Pharma A/S $ASND Stake Decreased by Westfield Capital Management Co. LP
MarketBeat

Westfield Capital Management Co. LP lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,259,909 shares of the…

thehindubusinessline.com - Nifty Prediction Today - February 26, 2026: Nifty futures: Intraday trend unclear, stay out
Nifty Prediction Today - February 26, 2026: Nifty futures: Intraday trend unclear, stay out
BusinessLine

Nifty 50 began today's session with a gap-up at 25,556 compared to yesterday's close of 25,483. It is now trading at 25,550, up 0.25 per cent. The advance/decline ratio stands at 30/20, showing a bullish bias. Tech Mahindra (up 1.9 per cent) is the…

fool.com - Motley Fool Transcribing - GoodRx (GDRX) Q4 2025 Earnings Call Transcript
GoodRx (GDRX) Q4 2025 Earnings Call Transcript
The Motley Fool

Thursday, Feb. 26, 2026 at 8 a.m. ET Chief Executive Officer — Wendy Barnes Chief Financial Officer — Chris McGinnis Chief Commercial Officer and President of Pharma Direct — Laura Jensen Need a quote from a Motley Fool…

rediff.com - Nandita Malik - Stock Market Today: Sensex, Nifty50 End Mixed In Volatile Trade
Stock Market Today: Sensex, Nifty50 End Mixed In Volatile Trade
Rediff.com

Indian stock markets experienced a day of seesaw trading as Sensex and Nifty ended nearly flat, influenced by global market cues, US-Iran talks, and strategic profit-booking. Sensex and Nifty ended almost flat after a volatile trading session…

globenewswire.com - AiCuris Anti-infective Cures AG - Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
GlobeNewswire

Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U.S. subsidiary Veloxis…

rediff.com - rediffGURU PANKAJ VYAVAHARE - I Was Laid Off Due To AI
I Was Laid Off Due To AI
Rediff.com

rediffGURU Pankaj Vyavahare, career counsellor and life coach, explains how you can survive in the age of AI. Are you someone who feels threatened by AI at work? Would you like to upskill so that you stay relevant? How can you future-proof your…

thehindu.com - The Hindu Bureau - Aurobindo arm's copy of Novartis drug gets U.S. FDA nod
Aurobindo arm's copy of Novartis drug gets U.S. FDA nod
The Hindu

Aurobindo Pharma subsidiary Eugia Pharma Specialities has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Everolimus Tablets in different strengths. The product is bioequivalent and…

yahoo.com - Laiba Immad - Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Yahoo!

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is among the 20 Best Investments in 2026. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best investment stocks on our list. TheFly reported on February 20 that Truist Securities…

newswire.ca - Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
CNW

Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week…

newswire.ca - genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
CNW

LYON, France, Feb. 26, 2026 /CNW/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's…

seekingalpha.com - SA Transcripts - GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
Seeking Alpha

GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Aubrey Reynolds - Director of Investor Relations Wendy Barnes - President, CEO & Director Christopher McGinnis - CFO & Treasurer Laura Jensen - Chief Commercial…

seekingalpha.com - SA Transcript Insights Editor - Agilent outlines $7.3B-$7.5B FY26 revenue target while expanding Ignite Operating System for margin growth (NYSE:A)
Agilent outlines $7.3B-$7.5B FY26 revenue target while expanding Ignite Operating System for margin growth (NYSE:A)
Seeking Alpha

Earnings Call Insights: Agilent Technologies (A) Q1 2026 CEO Padraig McDonnell reported '$1.8 billion in revenue, growing 4.4% on a core basis within our November guidance range.' McDonnell explained, 'End market conditions were largely consistent…

Receive a Daily briefing on Pharma Industry News

Get Started